九州大学 研究者情報
研究者情報 (研究者の方へ)入力に際してお困りですか?
基本情報 研究活動 教育活動 社会活動 病院臨床活動
藪内 英剛(やぶうち ひでたけ) データ更新日:2021.08.26

教授 /  医学研究院 保健学部門 医用量子線科学


主な研究テーマ
デジタルマンモグラフィの乳癌診断能の研究
キーワード:デジタルマンモグラフィ 乳癌
2006.04.
乳腺腫瘍のMRIによる診断
頭頸部腫瘍のMRIによる診断
造影ダイナミックMRIと拡散強調MRIを用いた乳癌の予後予測画像所見の研究
肺癌の化学療法効果を早期に予測する画像パラメーターの研究
キーワード:乳腺腫瘍、頭頸部腫瘍、肺癌
2000.04.
研究業績
主要著書
主要原著論文
1. Yabuuchi H, Kamitani T, Sagiyama K, Yamasaki Y, Hida T, Matsuura Y, Hino T, Murayama Y, Yasumatsu R, Yamamoto H, Characterization of parotid gland tumors: added value of permeability MR imaging to DWI and DCE-MRI, EUROPEAN RADIOLOGY, 10.1007/s00330-020-07004-3, 30, 12, 6402-6412, 2020.12, Objectives: To determine added value of permeability MRI in parotid tumor characterization to T2-weighted imaging (T2WI), semi-quantitative analysis of time-intensity curve (TIC), and intra-voxel incoherent motion diffusion-weighted imaging (IVIM-DWI).

Methods: This retrospective study was approved by the institutional review board, and the informed consent was waived. Sixty-one parotid tumors in 61 patients were examined using T2WI, IVIM-DWI, and permeability MRI. TIC patterns were categorized as persistent, washout, or plateau. Signal intensity ratio of lesion-to-muscle on T2WI, apparent diffusion coefficients (ADCs), D and f values from IVIM-DWI, and Ktrans, kep, Ve, and Vp values from permeability MRI were measured. Multiple comparisons were applied to determine whether any differences among 4 histopathologic types (pleomorphic adenomas, Warthin's tumors, other benign tumors, and malignant tumors) existed. Diagnostic accuracy was compared before and after modification diagnosis referring to permeability MRI. In a validation study, 60 parotid tumors in 60 patients were examined.

Results: ADC and D values of malignant tumors were significantly lower than those of benign tumors other than Warthin's tumors, but higher than those of Warthin's tumors. kep and Vp values of Warthin's tumors were significantly higher than those of malignant tumors. Multivariate analyses showed that TIC pattern, D, and kep values were suitable parameters. McNemar's test showed a significant increase of sensitivity (11/12, 92%) and specificity (46/49, 94%) with adding kep. The validation study yielded high sensitivity (14/16, 88%) and specificity (41/44, 93%).

Conclusion: Permeability MRI offers added value to IVIM-MRI and semi-quantitative TIC analysis of DCE-MRI in characterization of parotid tumors KEY POINTS: • Permeability MR imaging offers added value in the characterization of parotid gland tumors in combination with semi-quantitative TIC analysis and IVIM analyses with D parameter. • The combination of TIC pattern, D, and kep might facilitate accurate characterization of parotid gland tumor, thereby avoiding unnecessary surgery for benign tumors or delayed treatment for malignant tumors. • A combination of permeability and diffusion MR imaging can be used to guide the selection of an appropriate biopsy site..
2. Yabuuchi H, Kawanami S, Iwama E, Okamoto I, Kamitani T, Sagiyama K, Yamasaki Y, Honda H., Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups., Radiology, 10.1148/radiol.2017162204., 286, 2, 685-695, 2018.02, Purpose: To determine whether dual-input perfusion computed tomography (CT) can predict therapeutic response and prognosis in patients who underwent chemotherapy for non–small cell lung cancer (NSCLC).
Materials and Methods: The institutional review board approved this study and informed consent was obtained. Sixty-six patients with stage III or IV NSCLC (42 men, 24 women; mean age, 63.4 years) who underwent chemotherapy were enrolled. Patients were separated into three groups: those who received chemotherapy with bevacizumab (BV) (n = 20), those who received two-agent platinum-based therapy without BV (n = 25), and those who received other non-BV treatment (n = 21). Before treatment, pulmonary artery perfusion (PAP) and bronchial artery perfusion (BAP) of the tumors were calculated. Predictors of tumor reduction after two courses of chemotherapy and prognosis were identified by using univariate and multivariate analyses. Covariates included were age, sex, patient's performance status, baseline maximum diameter of the tumor, clinical stage, pretreatment PAP, and pretreatment BAP. For multivariate analyses, multiple linear regression analysis for tumor reduction rate and Cox proportional hazards model for prognosis were performed, respectively.
Results: Pretreatment BAP was independently correlated with tumor reduction rate after two courses of chemotherapy in the BV treatment group (P = .006). Pretreatment BAP was significantly associated with a highly cumulative risk of death (P = .006) and disease progression after chemotherapy (P = .015) in the BV treatment group. Pretreatment PAP and clinical parameters were not significant predictors of therapeutic effect or prognosis in three treatment groups.
Conclusion: Pretreatment BAP derived from dual-input perfusion CT seems to be a promising tool to help predict responses to chemotherapy with BV in patients with NSCLC..
3. Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, Jinnouchi M, Sakai S, Nakanishi Y, Honda H, Non–small cell lung cancer: detection of early response to chemotherapy by Using contrast-enhanced dynamic and diffusionweighted MR Imaging, Radiology, 261, 2, 598-604, 2011.11, Purpose: To evaluate the ability of dynamic contrast material–enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non–small cell lung cancer (NSCLC).
Materials and Methods: This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the fi rst course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time–signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coeffi cient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the fi rst course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coeffi cient. Kaplan-Meier curves of progressionfree survival and overall survival were generated, and comparisons between the group with a good response of the signifi cant parameter (upper 50th percentile) and that with a poor response of the signifi cant parameter (lower 50th percentile) were performed by using a two-sided logrank test.
Results: Signifi cant correlation was found only between early ADC change and fi nal tumor size reduction rate ( r 2 = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months ( P = .021), while median overall survival was 22.4 and 12.3 months, respectively ( P = .048).
Conclusion: ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC..
4. Yabuuchi H, Matsuo Y, Sunami S, Kamitani T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H., Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging., Eur Radiol. , 21, 1, 11-17, 2011.01.
5. Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H., Non-mass-like enhancement on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images., Eur J Radiol, 2009.09.
主要総説, 論評, 解説, 書評, 報告書等
主要学会発表等
学会活動
所属学会名
日本磁気共鳴医学会
日本医学放射線学会
日本血管造影・インターベンショナルラジオロジー学会
日本肺癌学会
日本呼吸器学会
学協会役員等への就任
2017.08~2019.08, 日本磁気共鳴学会, 代議員.
2014.04~2016.03, 日本医学放射線学会.
2011.02, 呼吸機能イメージング研究会, 世話人.
2010.02, 九州肺癌カンファレンス, 世話人.
2005.04, 北部九州画像診断フォーラム, 世話人.
2004.04, 福岡肺感染症研究会, 世話人.
2005.04, 福岡びまん性肺疾患研究会, 世話人.
2004.04, 福岡呼吸器カンファレンス, 世話人.
2001.04, 福岡胸部放射線研究会, 世話人.
2005.04, 胸部放射線研究会, 世話人.
学会大会・会議・シンポジウム等における役割
2016.01~2016.07.05, 第8回呼吸機能イメージング研究会, 座長(Chairmanship).
2012.09, 第26回胸部放射線研究会, 座長(Chairmanship).
2011.09.29~2011.10.01, 第39回日本磁気共鳴医学会大会, 座長(Chairmanship).
2006.10, 第20回胸部放射線研究会, 座長(Chairmanship).
学術論文等の審査
年度 外国語雑誌査読論文数 日本語雑誌査読論文数 国際会議録査読論文数 国内会議録査読論文数 合計
2020年度 231  12  245 
2019年度 73  81 
2018年度 24  33 
2017年度 20  10  31 
2016年度 15  10  26 
2015年度 19        19 
2014年度 13        13 
2013年度 14        14 
2012年度 11      16 
2011年度      
2010年度      
2009年度      
2008年度      
受賞
8th Japanese Society of Pulmonary Functional Imaging, Scientific Presentation Award, 呼吸機能イメージング研究会, 2016.01.
European Congress of Radiology 2015, Certificate of Merit, European Society of Radiology, 2015.03.
第15回九州肺癌カンファレンス 研究奨励賞, 九州肺癌カンファレンス , 2010.02.
第66回日本医学放射線学会Bronze Medal, 日本医学放射線学会, 2007.04.
平成18年日本医学放射線学会優秀論文賞, 日本医学放射線学会, 2006.04.
研究資金
科学研究費補助金の採択状況(文部科学省、日本学術振興会)
2006年度~2008年度, 基盤研究(C), 代表, 造影ダイナミック、拡散、スペクトロスコピー磁気共鳴を用いた乳癌予後予測所見の研究.
2012年度~2015年度, 基盤研究(C), 代表, 3TーMRIを用いた乳腺拡散テンソル画像の乳がん診療への応用.
2019年度~2021年度, 基盤研究(C), 代表, 吸気・呼気超高精細CTによる慢性閉塞性肺疾患患者の末梢気道病変の定量解析.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」